Omicron surge and the future of COVID-19 vaccinations

DOI: https://doi.org/10.13181/mji.bc.226066
Keywords: COVID-19 vaccine, Omicron, SARS-CoV-2 vaccine
Abstract viewed: 953 times
PDF downloaded: 701 times
HTML downloaded: 229 times
EPUB downloaded: 264 times

Abstract

The global surge of Omicron has caused significant concern. Omicron has caused new wave of infections in nations with adequate vaccine coverage. Omicron has around 30 mutations that are similar to the previous variant of concerns, possibly decreasing vaccine effectiveness (VE). Hence, the emergence of Omicron is predicted to be a significant public health challenge and may alter the future of COVID-19 vaccinations. Furthermore, other issues may affect vaccine policy in the future such as the never-ending vaccine inequity, waning immunity of current COVID-19 vaccines, decreasing VE against new emerging strains, and new findings regarding hybrid immunity. This literature review aimed to explore the possible steps forward using the most updated knowledge on COVID-19 vaccines and Omicron.

Downloads

Download data is not yet available.

Author Biography

Rizky Abi Rachmadi, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia

General Practicioner at RSUD dr. Haryoto, Lumajang

BMedSc(Hons) - Monash University

MD - University of Indonesia

References

  1. Center for Disease Control and Prevention. Potential rapid increase of Omicron variant infections in the United States. Center for Disease Control and Prevention; 2021.

  2. Mahase E. Covid-19: what do we know about Omicron sublineages? BMJ. 2022;376:o358. https://doi.org/10.1136/bmj.o358

  3. Zeng B, Gao L, Zhou Q, Yu K, Sun F. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis [Internet]. medRxiv [Preprint]. 2021. [posted 2021 Sep 26 cited 2022 Apr 5]. https://doi.org/10.1101/2021.09.23.21264048

  4. Hamady A, Lee J, Loboda ZA. Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses? Infection. 2022;50(1):11-25. https://doi.org/10.1007/s15010-021-01664-z

  5. Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning immune humoral response to BNT162b2 covid-19 vaccine over 6 months. N Engl J Med. 2021;385(24):e84. https://doi.org/10.1056/NEJMoa2114583

  6. Hayawi K, Shahriar S, Serhani MA, Alashwal H, Masud MM. Vaccine versus variants (3Vs): are the COVID-19 vaccines effective against the variants? A systematic review. Vaccines. 2021;9(11):1305. https://doi.org/10.3390/vaccines9111305

  7. Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021;21(10):626-36. https://doi.org/10.1038/s41577-021-00592-1

  8. Rosenberg ES, Dorabawila V, Easton D, Bauer UE, Kumar J, Hoen R, et al. Covid-19 vaccine effectiveness in New York State. N Engl J Med. 2022;386(2):116-27. https://doi.org/10.1056/NEJMoa2116063

  9. Leung K, Wu JT. Managing waning vaccine protection against SARS-CoV-2 variants. Lancet. 2022;399(10319):2-3. https://doi.org/10.1016/S0140-6736(21)02841-5

  10. Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis. 2022;114:252-60. https://doi.org/10.1016/j.ijid.2021.11.009

  11. Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Duration of protection against mild and severe disease by covid-19 vaccines. N Engl J Med. 2022;386(4):340-50. https://doi.org/10.1056/NEJMoa2115481

  12. Sheikh A, Kerr S, Woolhouse M, Mcmenamin J, Robertson C. Severity of Omicron variant of concern and vaccine effectiveness against symptomatic disease: national cohort with nested test negative design study in Scotland [Internet]. The University of Edindurgh. [Preprint]. 2021. Available from: https://www.research.ed.ac.uk/en/publications/severity-of-omicron-variant-of-concern-and-vaccine-effectiveness.

  13. Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, et al. Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa: a data linkage study. Lancet. 2022;399(10323):437-46. https://doi.org/10.1016/S0140-6736(22)00017-4

  14. Christie B. Covid-19: early studies give hope Omicron is milder than other variants. BMJ. 2021;375:n3144. https://doi.org/10.1136/bmj.n3144

  15. Collie S, Champion J, Moultrie H, Bekker LG, Gray G. Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa. N Engl J Med. 2022;386(5):494-6. https://doi.org/10.1056/NEJMc2119270

  16. Mahase E. Covid-19: Omicron and the need for boosters. BMJ. 2021;375:n3079. https://doi.org/10.1136/bmj.n3079

  17. Khan NA, Al-Thani H, El-Menyar A. The emergence of new SARS-CoV-2 variant (Omicron) and increasing calls for COVID-19 vaccine boosters-The debate continues. Travel Med Infect Dis. 2022;45:102246. https://doi.org/10.1016/j.tmaid.2021.102246

  18. Liu J, Chandrashekar A, Sellers D, Barrett J, Jacob-Dolan C, Lifton M, et al. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 omicron. Nature. 2022;603:493-6. https://doi.org/10.1038/s41586-022-04465-y

  19. Hart JD, Chokephaibulkit K, Mayxay M, Ong-Lim ALT, Saketa ST, Russell FM. COVID-19 vaccine boosters in the Asia-Pacific region in the context of Omicron. Lancet Reg Health West Pac. 2022:100404. https://doi.org/10.1016/j.lanwpc.2022.100404

  20. Putri SA. Mix-and-match, which covid-19 booster shot should I get? [Internet]. Jakarta's COVID-19 Response Team. 2022 [cited 2022 Mar 13]. Available from: https://corona.jakarta.go.id/en/artikel/cara-memilih-vaksin-booster-yang-tepat.

  21. Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Alroy-Preis S, et al. Protection against covid-19 by BNT162b2 booster across age groups. N Engl J Med. 2021;385(26):2421-30. https://doi.org/10.1056/NEJMoa2115926

  22. Rae M. Omicron: a failure to act with a global focus will continue the proliferation of new variants of covid-19. BMJ. 2021;375:n3095. https://doi.org/10.1136/bmj.n3095

  23. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, Yassine HM, Benslimane FM, Al Khatib HA, et al. Association of prior SARS-CoV-2 infection with risk of breakthrough infection following mRNA vaccination in Qatar. JAMA. 2021;326(19):1930-9. https://doi.org/10.1001/jama.2021.19623

  24. Shenoy P, Ahmed S, Paul A, Cherian S, Umesh R, Shenoy V, et al. Hybrid immunity versus vaccine-induced immunity against SARS-CoV-2 in patients with autoimmune rheumatic diseases. Lancet Rheumatol. 2022;4(2):e80-2. https://doi.org/10.1016/S2665-9913(21)00356-8

  25. Callaway E. COVID super-immunity: one of the pandemic's great puzzles. Nature. 2021;598(7881):393-4. https://doi.org/10.1038/d41586-021-02795-x

  26. Bates TA, McBride SK, Leier HC, Guzman G, Lyski ZL, Schoen D, et al. Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. Sci Immunol. 2022;7(68):eabn8014. https://doi.org/10.1126/sciimmunol.abn8014

Published
2022-04-22
How to Cite
1.
Burhan E, Rachmadi RA. Omicron surge and the future of COVID-19 vaccinations. Med J Indones [Internet]. 2022Apr.22 [cited 2024Jul.3];31(1):80-4. Available from: http://mji.ui.ac.id/journal/index.php/mji/article/view/6066
Issue
Vol. 31 No. 1 (2022): March
Section
Brief Communication

Copyright (c) 2022 Erlina Burhan, Rizky Abi Rachmadi

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with Medical Journal of Indonesia agree to the following terms:

  1. Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
  2. Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.